Connect with us

Hi, what are you looking for?

Alive Business PlanAlive Business Plan

Stock

US sues to block UnitedHealth’s $3.3 billion purchase of Amedisys

(Reuters) -The U.S. Department of Justice and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group (NYSE:UNH)’s $3.3 billion acquisition of Amedisys Inc (NASDAQ:AMED), citing concerns that the deal would reduce competition in the home health services market.

“Eliminating the competition between UnitedHealth and Amedisys would harm patients who receive home health and hospice services, insurers who contract for home health services, and nurses who provide home health and hospice services,” the DOJ said in a statement.

The attorneys generals of Maryland, New Jersey and New York are also suing to block the merger.

The Amedisys combination with Optum would be pro-competitive and further innovation, a spokesperson for Optum said. “We will vigorously defend against the DOJ’s overreaching interpretation of the antitrust laws.”

UnitedHealth operates Optum, a health services unit that provides analytics, research and pharmacy care services among others.

A spokesperson for Amedisys said the company remains committed to the transaction. “We look forward to supporting Optum in presenting our case,” the company said.

Following the news, UnitedHealth’s shares fell 1.1% in afternoon trading. Amedisys’ stock was down 2.1% at $90.75 in afternoon trading and is now 10% below UnitedHealth’s offer price of $101 per share.

UnitedHealth announced its intention to acquire Amedisys last year, but analysts anticipated regulatory scrutiny due to UnitedHealth’s presence in the home health sector.

The move follows a recent meeting between the companies’ executives and the DOJ aimed at addressing these concerns, according to Bloomberg News, which first reported the story on Tuesday.

To mitigate antitrust issues, Amedisys proposed selling over 100 locations to a private operator in Texas, contingent upon the deal’s completion, Stephens analyst Scott Fidel said.

“These remedies do not seem sufficient to satisfy the hardline Biden DOJ … Clearly, we’ll look to see whether a Trump DOJ decides to pursue or drop this case in 2025,” he added.

The Justice Department sued to halt UnitedHealth’s acquisition of Change Healthcare (NASDAQ:CHNG) in February 2022, but the transaction was completed later that year.

This post appeared first on investing.com
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    The Gateway Pundit, a far-right website, published a note from its editor on Saturday acknowledging that two election workers in Georgia did not engage...

    Latest News

    New majorities in Congress, particularly when the incoming party has a new leader, offer the rare chance for the institution to take a breath...

    Latest News

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Investing

    JAKARTA (Reuters) -Indonesia has asked Alphabet (NASDAQ:GOOGL)’s Google and Apple (NASDAQ:AAPL) to block Chinese fast fashion e-commerce firm Temu in their application stores in...



    Disclaimer: alivebusinessplan.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 alivebusinessplan.com